Atea Pharmaceuticals Inc. | Micro-cap | Healthcare
$3.33
-3.76%
| Atea Pharmaceuticals Stock Comparison:
Atea Pharmaceuticals vs VertexAtea Pharmaceuticals vs RegeneronAtea Pharmaceuticals vs Bright MindsAtea Pharmaceuticals vs Third Harmonic BioAtea Pharmaceuticals vs ProQR TherapeuticsAtea Pharmaceuticals vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0
Operating Income -41.3M
Net Income -37.2M
EPS (Diluted) $-0.44

Balance Sheet Metrics

Total Assets 440.0M
Total Liabilities 28.9M
Shareholders Equity 411.1M
Debt to Equity 0.07

Cash Flow Metrics

Operating Cash Flow -28.5M
Free Cash Flow -30.6M

Revenue & Profitability Trend

Atea Pharmaceuticals Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i000351.4M48.6M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i144.1M114.2M81.9M167.2M38.0M
Selling, General & Administrative i48.8M49.9M48.7M45.8M21.6M
Other Operating Expenses i-----
Total Operating Expenses i193.0M164.2M130.6M213.0M59.7M
Operating Income i-193.0M-164.2M-130.6M138.4M-11.0M
Operating Margin % i0.0%0.0%0.0%39.4%-22.7%
Non-Operating Items
Interest Income i25.5M29.2M11.2M213.0K83.0K
Interest Expense i-----
Other Non-Operating Income-----
Pre-tax Income i-167.5M-134.9M-119.5M138.6M-10.9M
Income Tax i925.0K1.0M-3.6M17.4M0
Effective Tax Rate % i0.0%0.0%0.0%12.6%0.0%
Net Income i-168.4M-136.0M-115.9M121.2M-10.9M
Net Margin % i0.0%0.0%0.0%34.5%-22.5%
Key Metrics
EBITDA i-192.5M-163.7M-130.4M138.4M-11.0M
EPS (Basic) i$-2.00$-1.63$-1.39$1.46$-0.51
EPS (Diluted) i$-2.00$-1.63$-1.39$1.37$-0.51
Basic Shares Outstanding i8426471583389750832453858282003721592441
Diluted Shares Outstanding i8426471583389750832453858282003721592441

Income Statement Trend

Atea Pharmaceuticals Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i64.7M143.8M188.5M764.4M850.1M
Short-term Investments i390.0M434.3M458.2M0-
Accounts Receivable i-----
Inventory i-----
Other Current Assets7.6M12.3M14.2M8.0M7.5M
Total Current Assets i462.4M590.5M660.9M772.4M863.5M
Non-Current Assets
Property, Plant & Equipment i1.2M1.8M2.4M166.0K5.0K
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets197.0K1.4M1.7M305.0K107.0K
Total Non-Current Assets i2.3M4.5M5.8M489.0K155.0K
Total Assets i464.7M595.0M666.7M772.9M863.6M
Liabilities
Current Liabilities
Accounts Payable i4.5M4.3M2.6M4.5M60.0K
Short-term Debt i800.0K760.0K721.0K197.0K-
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i18.6M32.4M18.5M56.9M315.8M
Non-Current Liabilities
Long-term Debt i842.0K1.6M2.4M0-
Deferred Tax Liabilities i-----
Other Non-Current Liabilities---5.9M36.0K
Total Non-Current Liabilities i7.2M7.4M7.7M5.9M36.0K
Total Liabilities i25.8M39.8M26.1M62.8M315.8M
Equity
Common Stock i84.0K83.0K83.0K83.0K82.0K
Retained Earnings i-364.2M-195.8M-59.9M56.0M-65.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i438.9M555.2M640.6M710.1M547.8M
Key Metrics
Total Debt i1.6M2.4M3.1M197.0K0
Working Capital i443.8M558.1M642.4M715.5M547.7M

Balance Sheet Composition

Atea Pharmaceuticals Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-168.4M-136.0M-115.9M121.2M-10.9M
Depreciation & Amortization i416.0K416.0K260.0K29.0K19.0K
Stock-Based Compensation i51.8M49.4M46.7M39.6M7.5M
Working Capital Changes i31.0K1.6M-2.7M-291.2M295.1M
Operating Cash Flow i-116.2M-84.5M-71.6M-130.4M291.6M
Investing Activities
Capital Expenditures i-0-1.9M-4.0K-26.0K
Acquisitions i-----
Investment Purchases i-461.2M-562.4M-545.4M00
Investment Sales i517.3M602.7M91.9M00
Investing Cash Flow i56.1M40.3M-455.4M-4.0K-26.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i--230.0K1.5M531.7M
Free Cash Flow i-135.5M-85.4M-122.9M-87.0M296.7M
Net Change in Cash i-60.1M-44.2M-526.8M-128.9M823.3M

Cash Flow Trend

Atea Pharmaceuticals Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -1.70
Forward P/E -2.20
Price to Book 0.75
PEG Ratio 0.20

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -32.38%
Return on Assets -20.16%

Financial Health

Current Ratio 19.17
Debt to Equity 0.34
Beta 0.25

Per Share Data

EPS (TTM) $-1.62
Book Value per Share $4.49
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
avir244.9M-1.700.75-32.38%0.00%0.34
Vertex 102.8B27.775.8322.77%31.86%8.89
Regeneron 61.2B14.642.0215.34%31.37%9.04
Bright Minds 246.0M0.285.44-30.79%0.00%0.27
Third Harmonic Bio 242.8M12.460.89-19.94%0.00%1.10
ProQR Therapeutics 241.2M-7.253.54-79.47%-231.45%25.17

Financial data is updated regularly. All figures are in the company's reporting currency.